Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 16/20 | 0.44 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.41 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.36 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3317593 | 0.99 | CTSS (0.45) | CTSSCTSKCTSLCTSBPRKAA2 | |
| SCHEMBL3322741 | 0.95 | CTSS (0.47) | CTSSCTSKCTSLCTSBPRKAA2 | |
| SCHEMBL3315529 | 0.95 | CTSS (0.47) | CTSSCTSKCTSLCTSBPRKAA2 | |
| Trifluoroacetic Acid SCHEMBL3320277 | 0.93 | CTSS (0.48) | CTSSCTSKCTSLCTSB | |
| Trifluoroacetic Acid SCHEMBL3918126 | 0.91 | CTSS (0.43) | CTSSCTSKCTSLCTSB | |
| Trifluoroacetic Acid SCHEMBL3921339 | 0.90 | CTSS (0.43) | CTSSCTSKCTSLCTSB | |
| Trifluoroacetic Acid SCHEMBL3321787 | 0.89 | CTSS (0.44) | CTSSCTSKCTSLCTSB | |
| SCHEMBL3318220 | 0.88 | CTSS (0.52) | CTSSCTSKCTSLCTSB | |
| Trifluoroacetic Acid SCHEMBL3322367 | 0.88 | CTSS (0.45) | CTSSCTSKCTSLCTSBPRKAA2 | |
| Trifluoroacetic Acid SCHEMBL3317815 | 0.88 | CTSS (0.45) | CTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED | 2010-04-29 | — | — | US | claimed |
| EP-2028182-A1 | Cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2009-02-25 | — | — | EP | claimed |
| EP-1972630-A1 | Purines as cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2008-09-24 | — | — | EP | claimed |
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED | 2010-04-29 | — | — | US | disclosed |
| EP-1972630-A1 | Purines as cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | CPN1, SERPINB1, PNP | CTSS 37/4885CTSK 135/4885CTSL 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.